Why Kymera Therapeutics (KYMR) Is Back In The Spotlight
Kymera Therapeutics (KYMR) drew fresh attention after announcing completion of patient enrollment in its KT-621 BROADEN2 Phase 2b trial for atopic dermatitis, along with updates on related asthma studies and upcoming scientific presentations.
The KT-621 news follows a strong run in Kymera Therapeutics' stock, with the share price at US$119.05 and a 30 day share price return of 15.14%. This adds to a 90 day share price return of 62.61% and a very large 3 year total shareholder return of more than 4x. This comes even though the 7 day share price return has pulled back 5.99% and the 1 year total shareholder return is 192.58%.
Scan other fast-moving biotech opportunities that show similar clinical momentum with our curated list of 19 high quality undiscovered gems alongside Kymera Therapeutics.
Kymera Therapeutics now has a widely watched clinical pipeline and a stock that has already rewarded early believers. The key issue for new investors is whether the current US$119 price fairly reflects that progress.
Most Popular Narrative: 6.6% Undervalued
The most followed valuation narrative for Kymera Therapeutics pegs fair value at $127.52, slightly above the last close at $119.05. This sets up a tight but important gap for investors to assess.
The analysts have a consensus price target of $127.52 for Kymera Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $155.0, and the most bearish reporting a price target of just $97.0.
Want to see why this fair value stretches so far beyond current losses? The key is how revenue, margins and future earnings are projected to evolve. The narrative lays out a detailed path that connects clinical milestones to those long range financial targets. If you want to understand what has to go right for Kymera Therapeutics to reach that price, the full story is worth reading.
Result: Fair Value of $127.52 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Kymera Therapeutics still faces meaningful risks, including high R&D spend against a reported net loss of $299.601 million and heavy reliance on partnership execution.
Find out about the key risks to this Kymera Therapeutics narrative.
Next Steps
With Kymera Therapeutics presenting both clear risks and encouraging rewards, it makes sense to move quickly and test the narrative against the underlying data yourself. To weigh the trade off more directly, start by reviewing the 1 key reward and 3 important warning signs.
Looking for more investment ideas beyond Kymera Therapeutics?
If you only focus on Kymera Therapeutics, you could miss other stocks that fit your style even better. Put a few minutes into widening your opportunity set.
- Target potential mispricings by scanning a curated 50 high quality undervalued stocks that may align with your preferred balance of quality and price.
- Strengthen your income stream by reviewing a hand picked 12 dividend fortresses that aim to combine yield with resilience.
- Dial down portfolio stress by checking a focused 74 resilient stocks with low risk scores that prioritise steadier risk profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com